


Bufrolin

Cat. No.:	HY-106481
CAS No.:	54867-56-0
Molecular Formula:	C ₁₈ H ₁₆ N ₂ O ₆
Molecular Weight:	356.33
Target:	GPR35; Histamine Receptor
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

Bufrolin is a Cromoglycate (histamine release inhibitor) analog and a high potency agonist of GPR35. Bufrolin promotes interactions between β -arrestin-2 and either human GPR35a or rat GPR35. Bufrolin also serves as antiallergic mast cell stabilizer and inhibit an anti-inflammatory response inducible by the internalization peptide. Bufrolin acts as an anti-inflammatory agent to be used in research of delivering pharmacol linked with internalization peptide^{[1][2][3]}.

REFERENCES

- [1]. MacKenzie AE, et al. The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. *Mol Pharmacol*. 2014 Jan;85(1):91-104.
- [2]. Tymianski M, et al. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory: United States, US8933013 B2. 2015-01-13.
- [3]. Church M K, et al. Comparison of sodium cromoglycate derivatives, anti-histamines and β -stimulants on histamine release from human lung in vitro[J]. *International Archives of Allergy and Immunology*, 1981, 66(Suppl. 1): 281-282.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA